Business Update Positive

2026-07-12 11:31

- Cipla received ESG ratings from Crisil ESG Ratings & Analytics Limited. The company has been assigned 'Crisil ESG 69' and 'Crisil Core ESG 66' ratings.

Business Update Neutral

2026-07-08 13:38

- Concall Schedule - Concall Date: July 23, 2026 - Concall Time: 1600 hrs IST

Business Update Positive

2026-07-04 19:00

CRITICAL RED FLAG DETECTED

- Management highlighted Cipla's strong performance with highest ever yearly revenue over ₹28,000 crores and healthy EBITDA (21%) and PAT (13.8%) margins for the last financial year. - Outlook for FY27 includes 12-15 USFDA filings and 40-50 filings over the next three years, with growth driven by new, complex products in respiratory, peptides, and biosimilars. - Strategic focus on leadership in India (respiratory, chronic diseases), differentiated products in North America, and strengthening presence in Europe and Emerging Markets. - R&D expenditure at ~7% of revenue, investing in future pipeline; cash position increased to ₹11,000 crores. - Addressing regulatory matters: Goa facility received VAI, Indore remediations completed and awaiting USFDA re-audit; working to restore Lanreotide supplies halted due to partner's USFDA observations. - Continued commitment to ESG, aiming for net-zero by 2050, and improving gender diversity in the workforce.

Business Update Positive

2026-07-03 18:47

- Reported highest ever yearly revenue of over ₹28,000 crores for FY26. - Achieved 21% EBITDA margin and 13.8% PAT margin in FY26. - India business grew 9% YoY to cross ₹12,500 crores; North America revenue was $780 million, and One Africa revenue was $483 million (7% growth). - Cash position increased from ₹5,000 crores to ₹11,000 crores in FY26, with approximately 7% of revenue (₹1,974 crores) invested in R&D. - Declared a final dividend of ₹30 per equity share for FY26. - Outlook includes 12-15 USFDA filings in FY27 (40-50 over 3 years) with a focus on complex, high-margin products to drive future growth. - Proactively addressing USFDA observations for a partner's Greece facility (Lanreotide supply) and awaiting re-audit for the Indore facility (remediations completed). - Committed to sustainability with a net-zero target by 2050, achieved 2.6 times water positivity, and utilizes 84% renewable electricity.

Governance Neutral

2026-06-25 22:02

- At the 90th Annual General Meeting held on June 25, 2026, members approved the appointment of M/s B S R & Co. LLP as Statutory Auditors for a term of five years, effective from the conclusion of the 90th AGM till the 95th AGM. - M/s Walker Chandiok & Co. LLP completed their second term and ceased to be the Statutory Auditors of the Company.

Governance Positive

2026-06-25 21:56

- The 90th Annual General Meeting was held on June 25, 2026, via video conferencing. - Proceedings included speeches by the Chairman and MD & GCEO, highlighting 90 years of operations. - Mr. Achin Gupta was welcomed as MD & Global CEO.

Governance Positive

2026-06-25 21:37

- The 90th Annual General Meeting (AGM) of Cipla Limited was held on June 25, 2026. - All resolutions proposed at the AGM, including the declaration of dividend on equity shares, were passed.

Business Update Negative

2026-06-25 15:05

- Cipla's ESG rating has been revised from 68 to 64 by ESGRisks.ai. - The revision is based on re-evaluation of publicly available and new information.

Governance Positive

2026-06-16 13:19

- The Board approved the appointment of Mr. Shivam Puri as CEO – One India Business and Senior Management Personnel, effective from July 1, 2026. - The Board also approved the grant of 11,360 stock options and 51,394 Employee Stock Appreciation Rights (ESARs) under existing schemes.

Governance Positive

2026-06-16 13:11

- Board approved the appointment of Mr. Shivam Puri as CEO – One India Business and Senior Management Personnel, effective July 1, 2026. - Also approved the grant of 11,360 Stock Options and 51,394 Employee Stock Appreciation Rights (ESARs) under existing schemes.

Business Update Positive

2026-06-11 14:06

- USFDA inspection at Cipla's Verna, Goa manufacturing facility from April 6-17, 2026. - The inspection has been classified as 'Voluntary Action Indicated (VAI)' by the USFDA on June 10, 2026.

Routine Neutral

2026-06-09 19:38

New Filing detected. See link for details.

Financials Positive

2026-06-08 22:06

- The Board of Directors has recommended a final dividend of ₹13/- per equity share for FY 2025-26, to be declared at the 90th Annual General Meeting. - Shareholders can submit requisite documents by Monday, June 15, 2026, to avail a nil or lower rate of tax deduction at source on this dividend.

Ownership Neutral

2026-06-04 19:37

- Cipla Limited allotted 44,770 fully paid-up equity shares (face value INR 2 each) on June 4, 2026. - This allotment is pursuant to the exercise of employee stock options/stock appreciation rights under the ESOS 2013-A and ESAR 2021 schemes. - The company's issued, subscribed, and paid-up share capital has increased to INR 1,61,56,90,632, comprising 80,78,45,316 equity shares.

Business Update Neutral

2026-06-02 17:01

- Investor Meeting Schedule - Meeting Date: 9th June 2026 - Investor: ICICI Securities India Investor Conference - Venue: Mumbai - Type of Meeting: In person

Business Update Neutral

2026-06-01 23:40

- Cipla Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - The report provides details on the company's ESG performance, policies, and governance practices. - It highlights manufacturing (69.03%) and trade (21.06%) as main activities. - Achin Gupta was appointed MD & GCEO effective April 1, 2026, replacing Umang Vohra.

Governance Positive

2026-06-01 23:29

- Cipla Limited's 90th Annual General Meeting (AGM) will be held on Thursday, 25th June, 2026, at 2:00 p.m. (IST) via Video Conferencing. - Key agenda items include the adoption of audited financial statements for FY 2025-26 and the declaration of a final dividend of ₹13/- per equity share (650%). - The AGM will also cover the re-appointment of Mr. Adil Zainulbhai as a director, appointment of Statutory Auditors, and ratification of Cost Auditor's remuneration. - The Record Date for the dividend is Friday, 5th June, 2026. Remote e-voting commences on June 21, 2026, and ends on July 24, 2026.

Business Update Neutral

2026-05-28 16:03

Cipla Limited informed about an upcoming in-person meeting with Citi India Conference scheduled for 5th June 2026 in Mumbai. The company noted that the schedule is subject to change due to unforeseen circumstances.

Business Update Positive

2026-05-15 18:35

Cipla management guided for North America to achieve a $1 billion run rate by the end of FY27 and expects strong double-digit growth in its India business for FY27-28. EBITDA margins are projected to be 18.5-20% for FY27, targeting over 20% in FY28, excluding Lanreotide's contribution for FY27. R&D spend will be sustained at 6-7% of revenue, focusing on complex products with 40-50 filings over three years, driving future growth. The company maintains a healthy net cash equivalent balance of INR 10,526 crores and is accelerating AI-led transformation.

Ownership Neutral

2026-05-14 12:12

Cipla Limited announced on May 14, 2026, the allotment of 17,915 fully paid-up equity shares of INR 2 each, following the exercise of employee stock options/stock appreciation rights under its ESOS 2013-A and ESAR 2021 schemes. Consequently, the company's issued, subscribed, and paid-up share capital increased to INR 1,61,56,01,092, comprising 80,78,00,546 equity shares of face value INR 2 each.

Business Update Neutral

2026-05-13 20:06

Cipla Ltd. announced the availability of the audio recording of its earnings conference call for the quarter and financial year ended March 31, 2026, which was held today. The recording is accessible on the company's website at https://www.cipla.com/audio/14837.

Governance Neutral

2026-05-13 13:24

Cipla's Board meeting on May 13, 2026, approved the 90th Annual General Meeting for June 25, 2026. The Board also approved the grant of employee stock options and Employee Stock Appreciation Rights (ESARs). M/s Joshi Apte & Associates was appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development and Senior Management Personnel, effective May 18, 2026.

Governance Positive

2026-05-13 13:18

Cipla's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th Annual General Meeting on June 25, 2026. The board also approved the grant of employee stock options and appreciation rights. Furthermore, M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27, and Mr Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development, effective May 18, 2026.

Governance Positive

2026-05-13 13:14

Cipla's Board of Directors, meeting on May 13, 2026, approved the convening of its 90th Annual General Meeting on June 25, 2026. Key decisions included the grant of employee stock options and ESARs, the appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27, and the appointment of Mr. Sushrut Kulkarni as President & Global Chief - Integrated Product Development (IPD) and Senior Management Personnel, effective May 18, 2026.

Governance Positive

2026-05-13 13:09

Cipla's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th Annual General Meeting on June 25, 2026. The board also approved the grant of employee stock options and appreciation rights (ESARs). M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development, effective May 18, 2026, strengthening the management team.

Financials Negative

2026-05-13 13:00

Consolidated Revenue ₹6,541 Cr vs ₹6,730 Cr (▼2.8% YoY), EBITDA ₹997 Cr vs ₹1,538 Cr (▼35.2% YoY), PAT ₹555 Cr vs ₹1,222 Cr (▼54.6% YoY). EBITDA Margin 15.2% vs 22.8% (▼760bps).

Financials Negative

2026-05-13 12:46

Cipla reported Consolidated Revenue of ₹6,541.20 Cr vs ₹7,049.68 Cr (▼7.2% YoY), EBITDA of ₹1,050.89 Cr vs ₹1,855.85 Cr (▼43.4% YoY), and PAT of ₹550.11 Cr vs ₹1,225.02 Cr (▼55.1% YoY) for the quarter ended 31st March, 2026. EBITDA Margin contracted to 16.1% from 26.3% (▼1020bps). The Board also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March, 2026.

Financials Negative

2026-05-13 12:44

Consolidated Revenue ₹6,541.20Cr vs ₹6,729.69Cr (▼2.79% YoY), EBITDA ₹954.95Cr vs ₹1,537.59Cr (▼37.89% YoY), PAT ₹542.51Cr vs ₹1,214.14Cr (▼55.33% YoY). EBITDA Margin 14.60% vs 22.85% (▼825bps). The Board also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March, 2026.

Financials Negative

2026-05-13 12:38

Cipla announced consolidated financial results for the quarter ended 31st March 2026. Consolidated Revenue stood at ₹6,541.20 Cr versus ₹6,729.69 Cr in the prior year quarter (▼2.80% YoY). EBITDA was ₹954.95 Cr versus ₹1,537.59 Cr (▼37.89% YoY), and PAT was ₹542.51 Cr versus ₹1,214.14 Cr (▼55.33% YoY). EBITDA Margin contracted to 14.60% from 22.85% (▼825 bps). The Board also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March 2026.

Business Update Positive

2026-04-23 09:48

Cipla received U.S. FDA final approval for the first AB-rated generic of Ventolin® HFA (Albuterol Sulfate Inhalation Aerosol), targeting the estimated $1.5 billion U.S. albuterol market. The product is expected to be launched in H1 of FY 2026-27 in the United States.

Business Update Negative

2026-04-17 16:34

CRITICAL RED FLAG DETECTED

Cipla announced a USFDA inspection at its Goa manufacturing facility from April 6-17, 2026. The routine cGMP and PAI concluded with two (2) inspectional observations in Form 483, which the company is committed to addressing comprehensively.

Routine Neutral

2026-04-16 19:54

New Filing detected. See link for details.

Routine Neutral

2026-04-09 17:59

Cipla Limited filed a compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, confirming timely processing of dematerialization requests by its Registrar and Share Transfer Agent, KFin Technologies Limited.

Governance Negative

2026-03-30 18:23

CRITICAL RED FLAG DETECTED

Mr. Umang Vohra resigned as Director and MD & CEO effective April 1, 2026, upon completing his term. Mr. Achin Gupta assumed charge as MD & Global CEO. Additionally, Mr. Saurabh Gambhir and Mr. Satyavan Manikani were categorized as Senior Management Personnel, also effective April 1, 2026.

Governance Negative

2026-03-30 18:20

CRITICAL RED FLAG DETECTED

Mr. Achin Gupta takes charge as Cipla's Managing Director and Global CEO. Mr. Saurabh Gambhir and Mr. Satyavan Manikani are appointed as Senior Management Personnel (SMPs) from April 1, 2026. Mr. Umang Vohra resigned as a Director, effective April 1, 2026, upon completion of his term as MD & Global CEO.

Governance Neutral

2026-03-26 22:15

Cipla Limited announced the results of its Postal Ballot. Members approved the appointment and remuneration of Mr. Achin Gupta as Director, Managing Director, and Global CEO, and the re-appointment of Mr. P.R. Ramesh as an Independent Director. All resolutions were passed with requisite majority.

Governance Negative

2026-03-26 20:39

CRITICAL RED FLAG DETECTED

Mr Pradeep Bhadauria, Global Chief Scientific Officer and member of the Management Council, has resigned from Cipla to pursue external interests. His last working day will be 31st March, 2026.

Governance Negative

2026-03-19 17:34

CRITICAL RED FLAG DETECTED

Cipla's Board approved a USD 100 million investment in Cipla (EU) for InvaGen's capital and working needs, and the amalgamation of Inzpera Healthsciences. Mr P R Ramesh was designated Vice-Chairman. Mr Robert Stewart will not seek re-appointment as an Independent Director upon completion of his term on 13th May 2026.

Governance Negative

2026-03-19 17:30

CRITICAL RED FLAG DETECTED

Cipla's Board meeting on March 19, 2026, appointed Mr. P R Ramesh as Lead Independent Director & Vice-Chairman, and Mr. Robert Stewart opted not to seek re-appointment as an Independent Director. The board also approved a USD 100 million investment in Cipla (EU) Limited and the amalgamation of Inzpera Healthsciences Limited.

Ownership Positive

2026-03-18 19:31

Cipla allotted 1,954 equity shares under its ESOS 2013-A and ESAR 2021 schemes on March 18, 2026. This allotment of fully paid-up shares of ₹2 each results in an increased paid-up share capital comprising 80,77,82,631 equity shares.

Business Update Negative

2026-03-09 22:52

Cipla USA Inc., a wholly owned subsidiary, initiated a recall of unexpired batches of Lanreotide Injection, leading to a temporary lack of supply to the market, as disclosed on March 9, 2026.

Business Update Positive

2026-03-02 20:07

Cipla Limited announced a 60:40 joint venture with Kemwell Biopharma Private Limited on March 2, 2026, to develop, manufacture, and commercialize biologic products in India for global markets. The initial investment will be up to INR 10 crores.

Business Update Positive

2026-03-02 19:30

Cipla Ltd. announced the incorporation of a new wholly-owned step-down subsidiary, 'Cipla Middle East Company', in Saudi Arabia on March 1, 2026. This entity aims to establish manufacturing and distribution of pharmaceutical products and hold marketing authorizations in KSA.

Business Update Negative

2026-02-26 17:21

CRITICAL RED FLAG DETECTED

Cipla's ESG rating for FY 2024-25 was revised downwards from 66 to 65 by NSE Sustainability. This revision is potentially due to a product recall by Cipla USA Inc., a subsidiary, in January 2026.

Governance Positive

2026-02-23 20:48

Cipla Ltd. issued a Notice of Postal Ballot dated 23rd January 2026 for shareholder approval. Resolutions include appointing Mr. Achin Gupta as Director, MD & GCEO, and approving his remuneration for 5 years. Also, re-appointing Mr. P R Ramesh as an Independent Director for 5 years.

Business Update Negative

2026-02-21 17:53

CRITICAL RED FLAG DETECTED

Cipla announced that the USFDA has classified the cGMP inspection at its supply partner Pharmathen International S.A.'s Rodopi, Greece facility as Official Action Indicated (OAI).

Business Update Neutral

2026-02-17 19:25

Cipla Limited intimated an in-person Analyst / Institutional Investor Meeting with Kotak Securities Conference on 23rd February 2026 in Mumbai, as per Regulation 30 of SEBI LODR Regulations.

Business Update Negative

2026-02-10 08:42

CRITICAL RED FLAG DETECTED

Cipla's subsidiary InvaGen received 2 USFDA Form 483 observations after a Pre-Approval Inspection (PAI) at its Hauppauge, New York manufacturing facility from Feb 2-9, 2026. The company committed to address the observations comprehensively.

Business Update Neutral

2026-02-08 14:51

Cipla announced that the Goods & Service Tax Department, Maharashtra, concluded an inspection/search on February 7, 2026. The company stated that no official document has been issued and there is no material impact on its financials or operations.

Business Update Negative

2026-02-05 23:34

CRITICAL RED FLAG DETECTED

Cipla disclosed that the Goods & Service Tax Department initiated inspection/search proceedings at its Maharashtra facilities on Feb 5, 2026, related to tax payments and input tax credit. The company is cooperating and states no financial or operational impact.

CIPLA

Cipla Limited

Price Chart

Filing History

Unlock Full History